tirzepatide law office in kentucky glp-1 constipation The maker of popular GLP-1 drugs Zepbound and Ozempic Lawsuits: FDA Warnings, Legal

Description

Food and Drug Administration adverse event reporting system

Recommended articles Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M Diabetes, Metabolic Syndrome and Obesity 2023, 16:1767-1774 Published Date: 14 June 2023 GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway Xiang J, Qin L, Zhong J, Xia N, Liang Y Diabetes, Metabolic Syndrome and Obesity 2023, 16:2433-2446 Published Date: 15 August 2023 Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study Cetiner S Diabetes, Metabolic Syndrome and Obesity 2026, 19:594898 Published Date: 31 March 2026 Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data Alourfi NM, Alorfi NM Diabetes, Metabolic Syndrome and Obesity 2026, 19:575375 Published Date: 14 May 2026 Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America Avelar LET, Sarlos P, Guarnieri C, Alvarez PP, Rojas GA, Rossiere N, Toro VA, Kamamoto C, Gomes RT, Nogueira A, Miot HA Clinical, Cosmetic and Investigational Dermatology 2026, 19:620566 Published Date: 17 June 2026